跳至主要内容
临床试验/NCT00258375
NCT00258375已完成2 期

A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel in Advanced Breast Cancer

NCIC Clinical Trials Group10 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2005年10月21日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
15
试验地点
10
主要终点
Objective response measured by RECIST criteria after accrual of 14 evaluable patients

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. OGX-011 may help docetaxel kill more tumor cells by making tumor cells more sensitive to the drug.

PURPOSE: This phase II trial is studying how well giving OGX-011 together with docetaxel works in treating women with locally advanced or metastatic breast cancer.

详细描述

OBJECTIVES:

Primary

  • Determine the efficacy of OGX-011 and docetaxel, in terms of objective tumor response rate, in women with locally advanced or metastatic breast cancer.

Secondary

  • Determine the tolerability and toxicity of this regimen in these patients.
  • Determine the time to progression and overall survival of patients treated with this regimen.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Objective response measured by RECIST criteria after accrual of 14 evaluable patients

次要结局

  • Toxicity

研究者

申办方类型
Network
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验